Table 2 Participant characteristics and outcomes by M. tuberculosis bacteremia status, ACTG A5221 STRIDE study
M. tuberculosis bacteremia | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Total | Yes | No | p-value a | |||||||
n/ | n | (%) | n/ | n | (%) | n/ | n | (%) | ||
Participant characteristics | ||||||||||
Male sex | 61/ | 90 | (67.8) | 9/ | 18 | (50.0) | 52/ | 72 | (72.2) | 0.092 |
Enrollment at an African site | 38/ | 90 | (42.2) | 9/ | 18 | (50.0) | 29/ | 72 | (40.3) | 0.595 |
Age (years)b | 37.0 (31.0, 45.0) | 33.0 (29.0, 37.0) | 38.0 (31.0, 45.4) | 0.056 | ||||||
CD4 count (cells/mm3)b | 81.0 (33.0, 131.0) | 35.0 (16.0, 62.0) | 91.0 (39.0, 146.5) | <0.001 | ||||||
HIV RNA (log10 copies/mL)b | 5.4 (5.0, 5.8) | 5.7 (5.4, 5.9) | 5.3 (4.8, 5.8) | 0.019 | ||||||
Presence of an AIDS-defining illness | 8/ | 90 | (8.9) | 2/ | 18 | (11.1) | 6/ | 72 | (8.3) | 0.658 |
Body mass index (BMI, kg/m2)b | 18.9 (17.2, 20.9) | 17.3 (15.6, 20.6) | 19.2 (17.9, 21.1) | 0.026 | ||||||
Hemoglobin ≤8.5 g/dL | 17/ | 90 | (18.9) | 8/ | 18 | (44.4) | 9/ | 72 | (12.5) | 0.005 |
Self-reported cough | 4/ | 90 | (4.4) | 1/ | 18 | (5.6) | 3/ | 72 | (4.2) | 1.000 |
Self-reported weight loss | 12/ | 90 | (13.3) | 4/ | 18 | (22.2) | 8/ | 72 | (11.1) | 0.248 |
Self-reported fever | 2/ | 90 | (2.2) | 0/ | 18 | (0.0) | 2/ | 72 | (2.8) | 1.000 |
Confirmed tuberculosis at entry | 50/ | 90 | (55.6) | 17/ | 18 | (94.4) | 33/ | 72 | (45.8) | <0.001 |
Early ART initiation | 42/ | 90 | (46.7) | 9/ | 18 | (50.0) | 33/ | 72 | (45.8) | 0.796 |
Outcome | ||||||||||
Immune reconstitution inflammatory syndrome | 11/ | 90 | (12.2) | 2/ | 18 | (11.1) | 9/ | 72 | (12.5) | 1.000 |
HIV-1 RNA level <400 copies/mL at week 48 | 69/ | 82 | (84.1) | 16/ | 16 | (100.0) | 53/ | 66 | (80.3) | 0.062 |
CD4 count increase ≥100 cells/mm3 at week 48 | 63/ | 85 | (74.1) | 15/ | 16 | (93.8) | 48/ | 69 | (69.6) | 0.059 |
Interruption or discontinuation of tuberculosis medications | 22/ | 90 | (24.4) | 7/ | 18 | (38.9) | 15/ | 72 | (20.8) | 0.131 |
Interruption or discontinuation of ARTc | 7/ | 85 | (8.2) | 3/ | 16 | (18.8) | 4/ | 69 | (5.8) | 0.120 |
Sputum smear conversion baseline to week 8d | 12/ | 35 | (34.3) | 7/ | 10 | (70.0) | 5/ | 25 | (20.0) | 0.008 |
Sputum culture conversion baseline to week 8d | 17/ | 23 | (73.9) | 3/ | 4 | (75.0) | 14/ | 19 | (73.7) | 1.000 |